Trials / Completed
CompletedNCT00672139
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness patients who have constipation caused by opioid pain relievers. This study will last 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylnaltrexone bromide |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2013-01-01
- Completion
- 2013-05-01
- First posted
- 2008-05-06
- Last updated
- 2018-03-07
- Results posted
- 2018-03-07
Locations
46 sites across 10 countries: United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Portugal, United Kingdom
Source: ClinicalTrials.gov record NCT00672139. Inclusion in this directory is not an endorsement.